Tiny radiation dose may tame stomach cancer with fewer side effects
NCT ID NCT03680586
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a very low dose of radiation (4 Gy) can effectively treat gastric MALT lymphoma, a type of stomach cancer. About 25 adults with stage I to IV disease will receive this ultra low-dose therapy. The goal is to kill tumor cells and shrink tumors while causing fewer side effects than standard radiation.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Early phase 1
The earliest testing in people: a first look at safety, in a very small group.
- Participants
-
25 people
The number who actually took part.
- Started
-
Feb 2019
- Expected to finish
-
Apr 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patients 18 years or older with stage I-IV MALT lymphoma involving the stomach. Other low grade lymphomas including follicular grade I/II and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) are ineligible * Patients must have biopsy-proven disease within the stomach. Patients with clinical and/or radiographic masses will have dimensions noted prior to therapy * Patients must have H. pylori testing which is negative within 6 months prior to treatment * Female patients of childbearing potential must have a negative serum pregnancy test (human chorionic gonadotropin \[hCG\]) within 2 weeks of protocol entry * Planned systemic therapy prior to, during, or after gastric radiation therapy is permitted however the timing of systemic therapy will be recorded and patients will be stratified according to receipt of systemic therapy * Patients must have the ability to give informed consent * Necessary treatment with antibiotics for reasons unrelated to gastric lymphoma is permitted however the timing and nature of the treatment will be recorded Exclusion Criteria: * Patients with aggressive B cell lymphoma histology, including diffuse large B cell lymphoma (DLBCL) and grade 3 follicular lymphoma * Patients with other histologic subtypes of low grade lymphoma (other than MALT) including chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) or follicular lymphoma * Patients with bulky tumors \> 10 cm in any dimension * Patients with a history of prior radiation to the stomach if re-treatment would exceed known gastric or surrounding critical structure (e.g., bowel, spinal cord) tolerance * Patients who are pregnant * Patients with scleroderma are ineligible
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Gastric mucosa-associated lymphoid tissue lymphoma are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.